The Effectiveness of Perovskia abrotanoides Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial.

IF 0.8 Q4 PHARMACOLOGY & PHARMACY
Journal of Research in Pharmacy Practice Pub Date : 2024-04-30 eCollection Date: 2023-07-01 DOI:10.4103/jrpp.jrpp_13_24
Maryam Sadat Tayebi, Nazila Poostiyan, Masoud Sadeghi Dinani, Erfaneh Ghassami, Rasool Soltani
{"title":"The Effectiveness of <i>Perovskia abrotanoides</i> Extract Topical Formulation on the Cutaneous Leishmaniasis: A Randomized Controlled Clinical Trial.","authors":"Maryam Sadat Tayebi, Nazila Poostiyan, Masoud Sadeghi Dinani, Erfaneh Ghassami, Rasool Soltani","doi":"10.4103/jrpp.jrpp_13_24","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. <i>Perovskia abrotanoides</i> (Brazambel) has shown significant effects against <i>Leishmania</i> parasites in some studies. This study aimed to investigate the effects of <i>P. abrotanoides</i> extract topical formulation on cutaneous leishmaniasis.</p><p><strong>Methods: </strong>In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (<i>n</i> = 18) and control (<i>n</i> = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime<sup>®</sup>). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.</p><p><strong>Findings: </strong>The percentage of reepithelialization in the experimental group (4<sup>th</sup> week: 64.44 ± 25.13; 8<sup>th</sup> week: 83.85 ± 11.54) was higher than the control group (4<sup>th</sup> week: 53.97 ± 25.88; 8<sup>th</sup> week: 76.27 ± 21.67); however, the differences were not statistically significant (<i>P</i> = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).</p><p><strong>Conclusion: </strong>The use of <i>P. abrotanoides</i> extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.</p>","PeriodicalId":17158,"journal":{"name":"Journal of Research in Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":0.8000,"publicationDate":"2024-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11071059/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Research in Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/jrpp.jrpp_13_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/7/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Despite many attempts to treat leishmaniasis, new approaches are necessary to reduce the burden of disease. Perovskia abrotanoides (Brazambel) has shown significant effects against Leishmania parasites in some studies. This study aimed to investigate the effects of P. abrotanoides extract topical formulation on cutaneous leishmaniasis.

Methods: In this randomized controlled clinical trial, patients with cutaneous leishmaniasis were assigned to experimental (n = 18) and control (n = 18) groups. Both groups received intralesional meglumine antimoniate (Glucantime®). The experimental group also received 5% Brazambel extract ointment once a day. The interventions continued until the complete healing of the lesions (reepithelialization) for a maximum of 8 weeks. The clinical response, defined as complete response (reepithelialization >75%), partial response (reepithelialization 50%-75%), or treatment failure (reepithelialization <50%), was compared between the groups.

Findings: The percentage of reepithelialization in the experimental group (4th week: 64.44 ± 25.13; 8th week: 83.85 ± 11.54) was higher than the control group (4th week: 53.97 ± 25.88; 8th week: 76.27 ± 21.67); however, the differences were not statistically significant (P = 0.252 and 0.494, respectively). Moreover, there was no significant difference between the experimental and control groups regarding the rate of complete healing (88.9% vs. 72.2%, respectively).

Conclusion: The use of P. abrotanoides extract 5% topical formulation does not affect the healing of cutaneous leishmaniasis.

Perovskia abrotanoides 提取物外用制剂对皮肤利什曼病的疗效:随机对照临床试验。
目的:尽管已多次尝试治疗利什曼病,但仍需要新的方法来减轻疾病负担。在一些研究中,Perovskia abrotanoides(Brazambel)对利什曼病寄生虫有显著效果。本研究旨在探讨P. abrotanoides提取物外用制剂对皮肤利什曼病的影响:在这项随机对照临床试验中,皮肤利什曼病患者被分为实验组(18 人)和对照组(18 人)。实验组和对照组均接受鞘内注射甲硝唑抗锑酸盐(Glucantime®)。实验组还接受每天一次的 5% Brazambel 提取物软膏治疗。干预措施一直持续到皮损完全愈合(再上皮化),最多持续 8 周。临床反应的定义为完全反应(上皮再化>75%)、部分反应(上皮再化50%-75%)或治疗失败(上皮再化结果:实验组的再上皮化百分比(第 4 周:64.44 ± 25.13;第 8 周:83.85 ± 11.54)高于对照组(第 4 周:53.97 ± 25.88;第 8 周:76.27 ± 21.67),但差异无统计学意义(P = 0.252 和 0.494)。此外,实验组和对照组在完全愈合率方面没有明显差异(分别为 88.9% 对 72.2%):结论:使用阿布罗塔诺苷提取物 5%局部制剂不会影响皮肤利什曼病的愈合。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Research in Pharmacy Practice
Journal of Research in Pharmacy Practice PHARMACOLOGY & PHARMACY-
自引率
0.00%
发文量
8
审稿时长
21 weeks
期刊介绍: The main focus of the journal will be on evidence-based drug-related medical researches (with clinical pharmacists’ intervention or documentation), particularly in the Eastern Mediterranean region. However, a wide range of closely related issues will be also covered. These will include clinical studies in the field of pharmaceutical care, reporting adverse drug reactions and human medical toxicology, pharmaco-epidemiology and toxico-epidemiology (poisoning epidemiology), social aspects of pharmacy practice, pharmacy education and economic evaluations of treatment protocols (e.g. cost-effectiveness studies). Local reports of medication utilization studies at hospital or pharmacy levels will only be considered for peer-review process only if they have a new and useful message for the international pharmacy practice professionals and readers.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信